Latest news with #CDMOs
Yahoo
5 days ago
- Business
- Yahoo
Cell Line Development Market Outlook Report 2025-2034: PromoCell, Novartis, Genscript Biotech, Sartorius, and Thermo Fisher Scientific Dominate the Industry
Booming Biologics and Biosimilars Market Drives Global Cell Line Development Surge; CDMOs and Technological Advancements Key to Growth Cell Line Development Market Dublin, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The "Cell Line Development Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" has been added to offering. The Global Cell Line Development Market was valued at USD 7.5 billion in 2024 and is estimated to grow at a CAGR of 10.2% to reach USD 19.7 billion by 2034. Market expansion is being fueled by a growing focus on biologics and biosimilars, particularly as the pharmaceutical industry shifts toward personalized therapies and precision medicine. The surge in demand for monoclonal antibodies, vaccines, and recombinant proteins has placed strong emphasis on the development of highly stable and productive cell lines. The increase in chronic illnesses-such as autoimmune diseases, cancer, and infectious disorders-has led to the rising adoption of biologics, which depend heavily on well-characterized cell lines. This has also elevated the need for quality-controlled production systems. Contract development and manufacturing organizations (CDMOs) have contributed significantly to market momentum. Small and mid-sized biotech firms are increasingly outsourcing their cell line development to CDMOs to reduce overhead costs and accelerate timelines, benefiting from their technical expertise, scalable platforms, and regulatory compliance with agencies like the FDA. This trend allows companies to focus on core competencies such as research and innovation while leveraging CDMOs for end-to-end services including cell line screening, clone selection, process optimization, and GMP manufacturing. These partnerships also offer access to advanced technologies, streamlined workflows, and proven quality assurance frameworks, enabling faster entry into clinical trials and reducing risks associated with internal capacity limitations. The reagents and media segment generated USD 3.4 billion in 2024. This segment continues to dominate due to its central role in cell growth and maintenance across both R&D and production stages. With a notable increase in the use of mammalian cells for biologics manufacturing, the demand for high-efficiency reagents and cell culture media has surged. A growing preference for protein-free and serum-free media is helping the segment gain traction, offering improved scalability, reduced risk of contamination, and consistency in large-scale production environments. Such media types are essential for regulatory approval and efficiency in biologics manufacturing, which demands stringent process control. In terms of cell type, the mammalian cells segment generated the highest revenue in 2024, accounting for 71.4%. Their dominance is linked to their superior ability to express human-compatible therapeutic proteins with accurate post-translational modifications. Widely used cell lines such as CHO and HEK-293 are favored in biologics production due to their robust protein folding, glycosylation, and scalability. Technological progress in gene editing tools, such as CRISPR-Cas9, combined with automation and high-throughput systems, continues to enhance the speed and stability of mammalian cell line development, further reinforcing their leadership in the market. The United States Cell Line Development Market was valued at USD 2.6 billion in 2024, driven by a combination of advanced biopharma infrastructure, high rates of chronic disease, and strong adoption of cutting-edge biologic therapies. The country's well-established pharmaceutical ecosystem, which includes top-tier biotech firms and extensive R&D investment, plays a pivotal role in expanding the market. Research institutions and innovation hubs across the US are also accelerating technological advancements in gene editing and automated platforms, leading to faster and more efficient development cycles. Government and private sector funding are also propelling innovation, further supporting the country's leadership in the field. Key companies operating in the Global Cell Line Development Market include PromoCell, Novartis, Genscript Biotech, Sartorius, Thermo Fisher Scientific, ProBioGen, Cytiva (Danaher Corporation), ASIMOV, Advanced Instruments, Sigma Aldrich (Merck KGaA), Eurofins Scientific, WuXi AppTec, Aragen Life Sciences, Fyonibio, and Lonza Group. Top-tier players in the cell line development space are heavily investing in technological innovations like automated cell screening platforms, single-use bioreactors, and CRISPR-based genome editing. Many companies are forming strategic alliances with biotech firms and CDMOs to enhance service offerings and expand production capabilities. Acquisitions are also a popular move to integrate novel technologies or gain regional access. Firms are focusing on R&D to develop serum-free and chemically defined media, helping improve regulatory compliance and scalability. Comprehensive Market Analysis and Forecast Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape Competitive landscape with Porter's Five Forces and PESTEL analysis Market size, segmentation, and regional forecasts In-depth company profiles, business strategies, financial insights, and SWOT analysis Key Attributes Report Attribute Details No. of Pages 145 Forecast Period 2024-2034 Estimated Market Value (USD) in 2024 $7.5 Billion Forecasted Market Value (USD) by 2034 $19.7 Billion Compound Annual Growth Rate 10.2% Regions Covered Global Key Topics CoveredChapter 1 Methodology and ScopeChapter 2 Executive Summary2.1 Industry 360 synopsis2.2 Key market trends2.2.1 Regional2.2.2 Products & services2.2.3 Source2.2.4 Cell line2.2.5 Application2.2.6 End use2.3 CXO perspectives: Strategic imperatives2.3.1 Key decision points for industry executives2.3.2 Critical success factors for market players2.4 Future outlook and strategic recommendationsChapter 3 Industry Insights3.1 Industry ecosystem analysis3.1.1 Supplier landscape3.1.2 Value addition at each stage3.1.3 Factors affecting the value chain3.2 Industry impact forces3.2.1 Growth drivers3.2.1.1 Growing vaccine production worldwide3.2.1.2 Increasing prevalence of cancer across the globe3.2.1.3 Technological innovations in cell line development3.2.1.4 Growing biotechnology industry3.2.2 Industry pitfalls and challenges3.2.2.1 Complex regulatory landscape3.2.2.2 Challenges related to stem cell research3.2.3 Market opportunities3.2.3.1 Emerging applications in personalized medicine and regenerative therapies3.2.3.2 Adoption of artificial intelligence in cell line optimization3.3 Growth potential analysis3.4 Regulatory landscape3.4.1 North America3.4.2 Europe3.4.3 Asia Pacific3.4.4 Latin America3.4.5 Middle East and Africa3.5 Future market trends3.6 Emerging therapeutic applications of CHO cell lines3.7 Technology landscape3.7.1 Current technological trends3.7.2 Emerging technologies3.8 Porter's analysis3.9 PESTEL analysisChapter 4 Competitive Landscape, 20244.1 Introduction4.2 Company market share analysis4.3 Company matrix analysis4.4 Competitive analysis of major market players4.5 Competitive positioning matrix4.6 Key developments4.6.1 Merger and acquisition4.6.2 Partnership and collaboration4.6.3 New product launches4.6.4 Expansion plansChapter 5 Market Estimates and Forecast, By Products & Services, 2021 - 2034 ($ Mn)5.1 Key trends5.2 Reagents and media5.3 Equipment5.3.1 Incubator5.3.2 Centrifuges5.3.3 Bioreactors5.3.4 Storage equipment5.3.5 Microscopes5.3.6 Electroporators5.3.7 Fluorescence-activated cell sorting5.3.8 Other equipment5.4 Accessories and consumables5.5 ServicesChapter 6 Market Estimates and Forecast, By Source, 2021 - 2034 ($ Mn)6.1 Key trends6.2 Mammalian6.2.1 Chinese Hamster Ovary (CHO)6.2.2 Human Embryonic Kidney (HEK)6.2.3 Baby Hamster Kidney (BHK)6.2.4 Murine myeloma6.2.5 Other mammalian sources6.3 Non-mammalian6.3.1 Insects6.3.2 AmphibiansChapter 7 Market Estimates and Forecast, By Cell Line, 2021 - 2034 ($ Mn)7.1 Key trends7.2 Recombinant7.3 Hybridomas7.4 Continuous cell lines7.5 Primary cell linesChapter 8 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)8.1 Key trends8.2 Bioproduction8.3 Drug discovery8.4 Toxicity testing8.5 Tissue engineering8.6 ResearchChapter 9 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)9.1 Key trends9.2 Pharmaceutical and biotechnology companies9.3 Academic and research institutes9.4 Contract research organizations (CROs)Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)10.1 Key trends10.2 North America10.2.1 U.S.10.2.2 Canada10.3 Europe10.3.1 Germany10.3.2 UK10.3.3 France10.3.4 Italy10.3.5 Spain10.3.6 Netherlands10.4 Asia Pacific10.4.1 China10.4.2 Japan10.4.3 India10.4.4 Australia10.4.5 South Korea10.5 Latin America10.5.1 Brazil10.5.2 Mexico10.6 Middle East and Africa10.6.1 South Africa10.6.2 Saudi Arabia10.6.3 UAEChapter 11 Company Profiles11.1 Advanced Instruments11.2 Aragen Life Sciences11.3 ASIMOV11.4 Cytiva (Danaher Corporation)11.5 Eurofins Scientific11.6 Fyonibio11.7 Genscript Biotech11.8 Lonza Group11.9 Novartis11.10 ProBioGen11.11 PromoCell11.12 Sartorius11.13 Sigma Aldrich (Merck KGaA)11.14 Thermo Fisher Scientific11.15 WuXi AppTecFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cell Line Development Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
17-07-2025
- Business
- Globe and Mail
Repligen to Report Second Quarter 2025 Financial Results
WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2025 financial results on Tuesday, July 29, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and six- month reporting periods ended June 30, 2025. The conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers and (646) 307-1963 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company's website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (800) 770-2030 for callers in the U.S., and (609) 800-9909 for international callers. Replay listeners must provide the passcode 7706699. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are 'inspiring advances in bioprocessing' for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at and follow us on LinkedIn. This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like 'believe,' 'expect,' 'may,' 'will,' 'should,' 'seek,' or 'could' and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Yahoo
09-06-2025
- Business
- Yahoo
Pharmaceutical Membrane Filtration Strategic Business Report 2025-2030 - Continuous Process Optimization Generates Demand, Expanding Biologics Strengthens Business Case for High-Precision Filtration
The global Pharmaceutical Membrane Filtration market, valued at $10.8 billion in 2024, is expected to reach $19.6 billion by 2030, growing at a 10.5% CAGR. Key drivers include rising biopharmaceutical demand, chronic disease prevalence, and advanced drug formulations. Regulatory requirements and technological advancements like continuous manufacturing and sustainable practices are reshaping the landscape. This report offers detailed insights into market growth, trends, and key players, helping businesses navigate this evolving sector effectively. Pharmaceutical Membrane Filtration Market Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Pharmaceutical Membrane Filtration - Global Strategic Business Report" report has been added to global market for Pharmaceutical Membrane Filtration was valued at US$10.8 Billion in 2024 and is projected to reach US$19.6 Billion by 2030, growing at a CAGR of 10.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business membrane filtration plays a pivotal yet often overlooked role in drug manufacturing, serving as a crucial mechanism for purifying and sterilizing various substances. But what makes this process indispensable to the industry? The stringent requirements in pharmaceutical production demand that all injectable drugs and intravenous solutions are completely free from contaminants, including microorganisms and particulates. Membrane filtration is uniquely equipped to meet these standards, removing unwanted particles without altering the essential properties of the drug. The growth in the pharmaceutical membrane filtration market is driven by several factors, including the expanding demand for biopharmaceuticals, the rising prevalence of chronic diseases, and the need for sophisticated drug formulations. Biologics and biosimilars, which require highly precise and sensitive filtration processes, are increasingly dominating the pharmaceutical market. This, in turn, is spurring the demand for advanced filtration technologies that can ensure the purity and effectiveness of these complex therapies. The trend towards outsourcing pharmaceutical production to CDMOs is also a significant growth driver, as these organizations seek scalable and dependable filtration solutions to meet the diverse needs of their clients. Additionally, recent global health events have heightened awareness of the importance of sterility in drug production, prompting pharmaceutical companies to invest heavily in cutting-edge filtration systems. Finally, the increasing focus on stringent quality controls and regulatory compliance is pushing companies to adopt advanced filtration technologies that can guarantee the safety and effectiveness of their Role Do Regulations Play in Shaping Pharmaceutical Filtration Practices?Pharmaceutical membrane filtration is tightly interwoven with regulatory compliance, which is at the core of pharmaceutical manufacturing. Regulatory bodies such as the FDA, EMA, and WHO impose strict guidelines that require drugs, particularly those administered via injection, to be free from contaminants, including microbial entities and pyrogens. As these guidelines become more stringent, the demand for reliable and efficient membrane filtration systems continues to grow. The industry is witnessing a surge in the adoption of single-use filtration systems, which reduce contamination risks and meet evolving regulatory requirements. Additionally, globalization has further complicated compliance, with pharmaceutical companies now required to meet various international standards. Membrane filtration systems have become indispensable tools, ensuring that products meet these increasingly complex regulations and quality controls across multiple Are Technological Advancements Shaping the Future of Filtration?Technological innovation is revolutionizing pharmaceutical membrane filtration, driving new trends that are shaping the future of drug manufacturing. A key trend is the transition towards continuous manufacturing, which requires filtration systems capable of operating without interruption, thereby increasing efficiency and reducing costs. Advances in membrane materials, such as the integration of nanotechnology and new polymers, are improving the performance and durability of filtration systems, ensuring that they can handle the increased demands of modern pharmaceutical processes. Sustainability is another growing focus, as companies seek to adopt environmentally friendly filtration technologies that reduce waste and energy consumption. Furthermore, the rise of personalized medicine is influencing the industry, as the production of specialized drugs for smaller patient populations demands highly precise filtration processes to maintain quality and ScopeReport Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as 3M Company, Alfa Laval, Amazon Filters Ltd., Danaher, Donaldson Company and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Filters segment, which is expected to reach US$11.7 Billion by 2030 with a CAGR of a 9.9%. The Systems segment is also set to grow at 12.8% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $2.8 Billion in 2024, and China, forecasted to grow at an impressive 14.0% CAGR to reach $4.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Segments Product Type (Filters, Systems, Accessories) Technique (Microfiltration, Reverse Osmosis, Ultrafiltration, Nanofiltration, Other Techniques) Application (Final Product Processing, Raw Material Filtration, Cell Separation, Water Purification, Air Purification) Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 93 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $10.8 Billion Forecasted Market Value (USD) by 2030 $19.6 Billion Compound Annual Growth Rate 10.5% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Tariff Impact on Global Supply Chain Patterns Global Economic Update Pharmaceutical Membrane Filtration - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Rising Demand for Biopharmaceuticals Spurs Growth in Membrane Filtration Market Continuous Manufacturing Throws the Spotlight on Advanced Filtration Systems Expanding Biologics Market Strengthens Business Case for High-Precision Filtration Single-Use Filtration Systems Propel Market Growth Regulatory Scrutiny Drives Adoption of Advanced Sterile Filtration Technologies Chronic Disease Prevalence Expands Addressable Market Opportunity Nanotechnology Innovations Accelerate Demand for Next-Generation Membranes Globalization of Pharmaceutical Supply Chains Spurs Need for Scalable Filtration Personalized Medicine Trends Generate Demand for Custom Filtration Solutions Sustainability Concerns Drive Adoption of Eco-Friendly Filtration Technologies R&D Investments Propel Market Expansion Energy-Efficient Filtration Systems Strengthen the Case for Green Manufacturing Practices Increased Focus on Biosimilars Propels the Adoption of Advanced Filtration Solutions Continuous Process Optimization Generates Market Demand FOCUS ON SELECT PLAYERS 3M Company Alfa Laval Amazon Filters Ltd. Danaher Donaldson Company Eaton Corporation GE Healthcare GEA Group Graver Technologies Koch Membrane Systems Meissner Filtration Products Merck Millipore Novasep Parker Hannifin Porvair Plc. Repligen Corporation Sartorius Stedim Biotech Sterlitech Corporation Synder Corporation Thermo Fisher Scientific For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Pharmaceutical Membrane Filtration Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-06-2025
- Business
- Yahoo
Pharmaceutical Membrane Filtration Strategic Business Report 2025-2030 - Continuous Process Optimization Generates Demand, Expanding Biologics Strengthens Business Case for High-Precision Filtration
The global Pharmaceutical Membrane Filtration market, valued at $10.8 billion in 2024, is expected to reach $19.6 billion by 2030, growing at a 10.5% CAGR. Key drivers include rising biopharmaceutical demand, chronic disease prevalence, and advanced drug formulations. Regulatory requirements and technological advancements like continuous manufacturing and sustainable practices are reshaping the landscape. This report offers detailed insights into market growth, trends, and key players, helping businesses navigate this evolving sector effectively. Pharmaceutical Membrane Filtration Market Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Pharmaceutical Membrane Filtration - Global Strategic Business Report" report has been added to global market for Pharmaceutical Membrane Filtration was valued at US$10.8 Billion in 2024 and is projected to reach US$19.6 Billion by 2030, growing at a CAGR of 10.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business membrane filtration plays a pivotal yet often overlooked role in drug manufacturing, serving as a crucial mechanism for purifying and sterilizing various substances. But what makes this process indispensable to the industry? The stringent requirements in pharmaceutical production demand that all injectable drugs and intravenous solutions are completely free from contaminants, including microorganisms and particulates. Membrane filtration is uniquely equipped to meet these standards, removing unwanted particles without altering the essential properties of the drug. The growth in the pharmaceutical membrane filtration market is driven by several factors, including the expanding demand for biopharmaceuticals, the rising prevalence of chronic diseases, and the need for sophisticated drug formulations. Biologics and biosimilars, which require highly precise and sensitive filtration processes, are increasingly dominating the pharmaceutical market. This, in turn, is spurring the demand for advanced filtration technologies that can ensure the purity and effectiveness of these complex therapies. The trend towards outsourcing pharmaceutical production to CDMOs is also a significant growth driver, as these organizations seek scalable and dependable filtration solutions to meet the diverse needs of their clients. Additionally, recent global health events have heightened awareness of the importance of sterility in drug production, prompting pharmaceutical companies to invest heavily in cutting-edge filtration systems. Finally, the increasing focus on stringent quality controls and regulatory compliance is pushing companies to adopt advanced filtration technologies that can guarantee the safety and effectiveness of their Role Do Regulations Play in Shaping Pharmaceutical Filtration Practices?Pharmaceutical membrane filtration is tightly interwoven with regulatory compliance, which is at the core of pharmaceutical manufacturing. Regulatory bodies such as the FDA, EMA, and WHO impose strict guidelines that require drugs, particularly those administered via injection, to be free from contaminants, including microbial entities and pyrogens. As these guidelines become more stringent, the demand for reliable and efficient membrane filtration systems continues to grow. The industry is witnessing a surge in the adoption of single-use filtration systems, which reduce contamination risks and meet evolving regulatory requirements. Additionally, globalization has further complicated compliance, with pharmaceutical companies now required to meet various international standards. Membrane filtration systems have become indispensable tools, ensuring that products meet these increasingly complex regulations and quality controls across multiple Are Technological Advancements Shaping the Future of Filtration?Technological innovation is revolutionizing pharmaceutical membrane filtration, driving new trends that are shaping the future of drug manufacturing. A key trend is the transition towards continuous manufacturing, which requires filtration systems capable of operating without interruption, thereby increasing efficiency and reducing costs. Advances in membrane materials, such as the integration of nanotechnology and new polymers, are improving the performance and durability of filtration systems, ensuring that they can handle the increased demands of modern pharmaceutical processes. Sustainability is another growing focus, as companies seek to adopt environmentally friendly filtration technologies that reduce waste and energy consumption. Furthermore, the rise of personalized medicine is influencing the industry, as the production of specialized drugs for smaller patient populations demands highly precise filtration processes to maintain quality and ScopeReport Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as 3M Company, Alfa Laval, Amazon Filters Ltd., Danaher, Donaldson Company and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Filters segment, which is expected to reach US$11.7 Billion by 2030 with a CAGR of a 9.9%. The Systems segment is also set to grow at 12.8% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $2.8 Billion in 2024, and China, forecasted to grow at an impressive 14.0% CAGR to reach $4.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Segments Product Type (Filters, Systems, Accessories) Technique (Microfiltration, Reverse Osmosis, Ultrafiltration, Nanofiltration, Other Techniques) Application (Final Product Processing, Raw Material Filtration, Cell Separation, Water Purification, Air Purification) Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 93 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $10.8 Billion Forecasted Market Value (USD) by 2030 $19.6 Billion Compound Annual Growth Rate 10.5% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Tariff Impact on Global Supply Chain Patterns Global Economic Update Pharmaceutical Membrane Filtration - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Rising Demand for Biopharmaceuticals Spurs Growth in Membrane Filtration Market Continuous Manufacturing Throws the Spotlight on Advanced Filtration Systems Expanding Biologics Market Strengthens Business Case for High-Precision Filtration Single-Use Filtration Systems Propel Market Growth Regulatory Scrutiny Drives Adoption of Advanced Sterile Filtration Technologies Chronic Disease Prevalence Expands Addressable Market Opportunity Nanotechnology Innovations Accelerate Demand for Next-Generation Membranes Globalization of Pharmaceutical Supply Chains Spurs Need for Scalable Filtration Personalized Medicine Trends Generate Demand for Custom Filtration Solutions Sustainability Concerns Drive Adoption of Eco-Friendly Filtration Technologies R&D Investments Propel Market Expansion Energy-Efficient Filtration Systems Strengthen the Case for Green Manufacturing Practices Increased Focus on Biosimilars Propels the Adoption of Advanced Filtration Solutions Continuous Process Optimization Generates Market Demand FOCUS ON SELECT PLAYERS 3M Company Alfa Laval Amazon Filters Ltd. Danaher Donaldson Company Eaton Corporation GE Healthcare GEA Group Graver Technologies Koch Membrane Systems Meissner Filtration Products Merck Millipore Novasep Parker Hannifin Porvair Plc. Repligen Corporation Sartorius Stedim Biotech Sterlitech Corporation Synder Corporation Thermo Fisher Scientific For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Pharmaceutical Membrane Filtration Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
27-05-2025
- Business
- Yahoo
Healthcare CDMO Strategic Research Report 2025: Market to Surpass $350 Billion by 2030 - Rising Outsourcing of Drug Discovery and Early-Stage Development Strengthens Demand
This comprehensive report delves into market trends, drivers, and forecasts. Key growth areas include biologics manufacturing and personalized medicine, with significant contributions from technological advancements like continuous production and digital technologies. Regions like the U.S. and China showcase robust growth, emphasizing the critical role of CDMOs in drug development and manufacturing. Healthcare Contract Development and Manufacturing Organization Market Dublin, May 27, 2025 (GLOBE NEWSWIRE) -- The "Healthcare Contract Development and Manufacturing Organization - Global Strategic Business Report" report has been added to global market for Healthcare Contract Development and Manufacturing Organization was valued at US$351.7 Billion in 2024 and is projected to reach US$547.1 Billion by 2030, growing at a CAGR of 7.6% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Healthcare Contract Development and Manufacturing Organization market. Healthcare Contract Development and Manufacturing Organizations (CDMOs) are critical partners in the pharmaceutical and biotechnology industries, providing outsourced services for drug development, manufacturing, and commercialization. CDMOs offer a range of services, from early-stage drug discovery and development to clinical trials and commercial-scale production. By outsourcing to CDMOs, pharmaceutical companies can reduce costs, accelerate time-to-market, and focus on core competencies such as research and marketing. The rise of biologics, biosimilars, and personalized medicine has further expanded the role of CDMOs, as these complex therapies require specialized manufacturing expertise that many pharmaceutical companies lack in-house. What Factors Are Driving the Growth in the Healthcare CDMO Market?The growth in the healthcare CDMO market is driven by several factors, including the increasing outsourcing of drug development and manufacturing activities by pharmaceutical and biotechnology companies. The rising demand for biologics, biosimilars, and personalized medicine is fueling the need for specialized manufacturing capabilities that CDMOs provide. Additionally, the need for faster time-to-market and cost-effective production solutions is pushing pharmaceutical companies to partner with CDMOs. Technological advancements in bioprocessing and continuous manufacturing are further driving the growth of the CDMO market. Furthermore, regulatory pressures and the complexity of drug development are encouraging pharmaceutical companies to outsource more of their development and manufacturing processes, creating new opportunities for CDMOs. What Are the Key Segments of the CDMO Market?Service types include contract development (drug discovery, preclinical and clinical development) and contract manufacturing (small molecule production, biologics manufacturing). CDMOs serve various segments, including pharmaceuticals, biotechnology, and medical device companies. The demand for biologics and biosimilars is driving significant growth in the CDMO market, particularly for services related to monoclonal antibody production, cell and gene therapy, and vaccine manufacturing. The rise of personalized medicine is also contributing to the expansion of the CDMO market, as it requires flexible manufacturing capabilities to produce customized Are Technological Advancements Driving Innovation in CDMOs?Technological innovations are enhancing the capabilities of CDMOs, particularly in the areas of biologics manufacturing and continuous production. Advances in bioprocessing technologies, such as single-use systems and modular production facilities, are enabling CDMOs to scale up production more efficiently and with greater flexibility. Continuous manufacturing technologies, which allow for the uninterrupted production of pharmaceuticals, are also gaining traction in the CDMO sector, reducing production costs and improving product quality. Additionally, the integration of digital technologies, such as data analytics and automation, is enabling CDMOs to optimize production processes, ensure compliance with regulatory standards, and reduce the risk of human ScopeKey Insights: Market Growth: Understand the significant growth trajectory of the Contract Manufacturing segment, which is expected to reach US$425.9 Billion by 2030 with a CAGR of a 8.1%. The Contract Development segment is also set to grow at 6.0% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $97.9 Billion in 2024, and China, forecasted to grow at an impressive 7.1% CAGR to reach $84.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Albany Molecular Research, Inc., Catalent, Inc., Covance, Inc., DPT Laboratories Ltd., Flex and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 89 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $351.7 Billion Forecasted Market Value (USD) by 2030 $547.1 Billion Compound Annual Growth Rate 7.6% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Tariff Impact on Global Supply Chain Patterns Global Economic Update Healthcare Contract Development and Manufacturing Organization - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Rising Outsourcing of Pharmaceutical and Biotech Manufacturing Drives Growth in Healthcare CDMO Market Growing Demand for Biologics and Biosimilars Propels Market Opportunities for CDMOs Increasing Focus on Speed-to-Market for Drug Development Strengthens Business Case for CDMOs Technological Advancements in Bioprocessing and Cell Therapy Manufacturing Drives Adoption of CDMO Services Expansion of Personalized Medicine and Gene Therapies Fuels Growth in the CDMO Sector Rising Pharmaceutical R&D Expenditure Expands Addressable Market for CDMOs Increasing Demand for Flexible Manufacturing and Modular Production Solutions Expands Market Opportunities Technological Innovations in Continuous Manufacturing and Process Optimization Propel Market Growth Rising Outsourcing of Drug Discovery and Early-Stage Development Strengthens Market Demand Increasing Adoption of Single-Use Technologies in Biopharmaceutical Manufacturing Drives Growth in CDMO Market Rising Demand for Contract Manufacturing in Cell and Gene Therapy Expands CDMO Market Horizons FOCUS ON SELECT PLAYERS:Some of the 33 companies featured in this report Albany Molecular Research, Inc. Catalent, Inc. Covance, Inc. DPT Laboratories Ltd. Flex IQVIA Holdings, Inc. Jabil Lonza Group Ltd. Nextpharma Technologies Recipharm AB Sanmina Corporation Siegfried Holding AG Thermo Fisher Scientific, Inc. Unither Vetter For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Healthcare Contract Development and Manufacturing Organization Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
